ds-1001b
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 19, 2017 (NCT03030066)
Timeline
Indications
Mechanism of action
IDH1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12- Mol. weight
- 608.93 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650282 ↗
Also known as
- ds-1001b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05814536 | Phase 1 | May 6, 2023 | AnHeart Therapeutics Inc. |
| NCT05303519 | Phase 2 | Jan 31, 2023 | AnHeart Therapeutics Inc. |
| NCT05577416 | Early Phase 1 (Phase 1) | Oct 11, 2022 | AnHeart Therapeutics Inc., Melbourne Health, Walter and Eliza Hall Institute of Medical Research |
| NCT04458272 | Phase 2 | Jul 8, 2020 | Daiichi Sankyo |
| NCT03030066 | N/A | Jan 19, 2017 | Daiichi Sankyo |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnHeart Therapeutics Inc. | For profit | 3 | 2 | 2 | 2022 |
| Daiichi Sankyo | For profit | 2 | 2 | 2 | 2017 |
| Melbourne Health | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Walter and Eliza Hall Institute of Medical Research | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1